Taken together, wobble vaccines represent a novel method for anticipating and preventing viral escape with promising applications in SARS-CoV-2, influenza, HIV, and beyond.
Abstract
Vaccination remains the most successful preventative measure against viral infection, but methods to stably deter rapidly-evolving pathogens have remained elusive. Vaccines capable of incorporating and anticipating viral evolution could address current challenges in seasonal vaccination efforts against SARS-CoV-2 and influenza where economic and disease burdens remain high despite decades of combined study. Rare epitope suppression (RES) is an underutilized concept within vaccine design, where humoral epitope targeting can be molded using complex antigen pools. Based in mRNA vaccine technology, ‘wobble vaccines’ represent the novel application of RES to human pathogens designed to anticipate and resist viral evolution. To establish this platform, public SARS-CoV-2 sequencing data was compiled from the first two years of the COVID-19 pandemic to identify high-diversity sites across the receptor binding domain (RBD) of the spike protein. Wobble RBD (WobbRBD) libraries reflecting that entropy were synthesized and incorporated into established self-amplifying (SA) vaccine constructs. Animals immunized with these complex antigen pools showed no obvious adverse effects. By three days-post vaccination, WobbRBD stimulated robust primary immune activation with distinctive characteristics compared to traditional single-strain vaccine modalities. By day 14, germinal centers, class switching, and antibody-secreting cells were induced, creating potent SARS-CoV-2 spike-binding IgG antibodies. Despite similar overall activation profiles, WobbRBD generated significantly increased breadth against SARS-CoV-2 variant spikes in comparison to single-strain controls – even against future-emerging strains. Taken together, wobble vaccines represent a novel method for anticipating and preventing viral escape with promising applications in SARS-CoV-2, influenza, HIV, and beyond.
The feasibility of the m8Δ/AAV1 platform is demonstrated as a versatile viral-vectored multipathogen vaccine platform capable of integrating protozoan and viral antigens, providing a rationale for further preclinical optimization and clinical evaluation of next generation multipathogen vaccines targeting both endemic a...
Yuna Sato, Yutaro Yamamoto, A. Hasyim et al.· Frontiers in Immunology· 0 citations
The review emphasizes the necessity of global surveillance programs to monitor viral evolution in real-time and calls for a collaborative, interdisciplinary approach to create more robust and future-proof vaccination strategies, thereby mitigating the risk of vaccine-driven viral and ensuring long term efficacy.
Z. Al-Talabani, Anmar Ayoub Al-Obaidi, Shahad Abdul Majeed Aswad· SAR Journal of Pathology and...· 0 citations
A bivalent chimeric inactivated vaccine, designated cHANA, is developed by combining two individually rescued chimeric inactivated viruses, cHANA1 and cHANA2, by combining two individually rescued chimeric inactivated viruses to eliciting more potent cross-reactive antibody responses and T cell immunity in mice.
Mengchan Hao, Yiwei Guan, Meng Xu et al.· Emerging Microbes and Infect...· 0 citations
Depletion experiments revealed that booster-induced immunity was predominantly mediated by cross-reactive antibodies, with the highest levels after breakthrough infections and the lowest after a primary WT infection, providing functional insights into the antibody specificities associated with imprinting effects follow...
Iris Medits-Weiss, Dominik Moll, D. Springer et al.· Scientific Reports· 0 citations
The efficacy of viral vector-based vaccines is essential to provide long-term protection and prevention of emerging epidemics and pandemics in parallel to other vaccine platforms and the ability to quickly react to emerging variants and their effects on vaccine efficacy is important.
Kenneth Lundstrom· Exploration of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.